{"id":"bornaprine","rwe":[],"tags":[{"label":"bornaprine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N04AA11","category":"atc"},{"label":"Active","category":"status"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Muscarinic Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["bornaprine","bornaprine hydrochloride","bornaprine HCl"],"offLabel":[],"synonyms":["bornaprine","bornaprine hydrochloride","bornaprine HCl"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"bornaprine","explanation":"This means that it helps to regulate the balance of chemicals in the brain that are involved in mood and other functions. By doing so, it may help to alleviate symptoms of certain conditions, although its exact mechanism of action is not well understood.","oneSentence":"Bornaprine is thought to work by modulating the activity of certain neurotransmitters in the brain.","technicalDetail":"Bornaprine is believed to act as a dopamine receptor antagonist, which may contribute to its therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/390","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BORNAPRINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:01:55.869534","biosimilars":[],"competitors":[{"drugName":"trihexyphenidyl","drugSlug":"trihexyphenidyl","fdaApproval":"1949-05-13","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"biperiden","drugSlug":"biperiden","fdaApproval":"1959-09-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"metixene","drugSlug":"metixene","fdaApproval":"","relationship":"same-class"},{"drugName":"procyclidine","drugSlug":"procyclidine","fdaApproval":"1955-07-27","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"profenamine","drugSlug":"profenamine","fdaApproval":"","relationship":"same-class"}],"genericName":"bornaprine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"trihexyphenidyl","brandName":"trihexyphenidyl","genericName":"trihexyphenidyl","approvalYear":"1949","relationship":"same-class"},{"drugId":"biperiden","brandName":"biperiden","genericName":"biperiden","approvalYear":"1959","relationship":"same-class"},{"drugId":"metixene","brandName":"metixene","genericName":"metixene","approvalYear":"","relationship":"same-class"},{"drugId":"procyclidine","brandName":"procyclidine","genericName":"procyclidine","approvalYear":"1955","relationship":"same-class"},{"drugId":"profenamine","brandName":"profenamine","genericName":"profenamine","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003699","UNII":"9M363FGA7J","CHEBI":"CHEBI:135406","INN_ID":"3897","RXNORM":"19610","UMLSCUI":"C0053947","ChEMBL_ID":"CHEMBL4297087","KEGG_DRUG":"D07302","DRUGBANK_ID":"DB13619","PUBCHEM_CID":"30160","SECONDARY_CAS_RN":"26908-91-8","MESH_SUPPLEMENTAL_RECORD_UI":"C006088"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N04AA11","allCodes":["N04AA11"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"BORNAPRINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bornaprine is a small molecule drug in the bornaprine class, but its target and commercial status are unknown. It is not clear if it has been approved by the FDA or if it is patented or generic. The drug's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand its clinical use and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}